throbber
UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`MEDTRONIC, INC. and MEDTRONIC VASCULAR, INC.,
`Petitioners,
`
`v.
`
`TELEFLEX INNOVATIONS S.A.R.L.,1
`Patent Owner
`
`IPR2020-01341
`Patent 8,142,413 B2
`
`PETITIONERS MEDTRONIC, INC. AND MEDTRONIC VASCULAR,
`INC.’S NOTICE OF APPEAL UNDER 37 C.F.R. § 90.2(a)
`
`
`
`
`
`
`
`1
`The caption in the papers before the Patent Trial and Appeal Board
`sometimes listed Teleflex Life Sciences Limited as the Patent Owner and
`sometimes listed Teleflex Innovations S.A.R.L. Appellants Medtronic, Inc. and
`Medtronic Vascular, Inc. believe the correct party is Teleflex Life Sciences
`Limited, but have used Teleflex Innovations S.A.R.L. to match the caption shown
`on the Board’s Final Written Decision.
`
`
`
`

`

`Pursuant to 35 U.S.C. §§ 141-144, 319, and 37 C.F.R.§ 90.2(a), notice is
`
`hereby given that Petitioners Medtronic, Inc. and Medtronic Vascular, Inc.
`
`(“Medtronic”) appeal to the United States Court of Appeals for the Federal Circuit
`
`from the Final Written Decision (“Final Written Decision”) (Paper No. 93, dated
`
`February 7, 2022) entered by the United States Patent and Trademark Office,
`
`Patent Trial and Appeal Board (“Board”) in IPR2020-01341, and from all
`
`underlying orders, decisions, rulings, and opinions. A copy of the Final Written
`
`Decision is attached hereto as Exhibit A.
`
`In accordance with 37 C.F.R. § 90.2(a)(3)(ii), Medtronic further indicates
`
`that the issues on appeal may include, but are not limited to, whether the Board
`
`erred in determining that claims 1, 2, 4, 5, and 7-14 of U.S. Patent Number
`
`8,142,413 were not shown to be unpatentable under 35 U.S.C. § 102 or § 103, any
`
`findings supporting or related to the Board’s determination, and all other issues
`
`decided adversely to Medtronic in any order, decision, ruling, and/or opinion,
`
`including but not limited to the Board’s failure to properly consider evidence of
`
`record, the Board’s legal errors in undertaking the anticipation and obviousness
`
`analyses, and the Board’s findings that conflict with the evidence of record and are
`
`not supported by substantial evidence.
`
`Simultaneous with this submission, a copy of this Notice of Appeal is being
`
`filed through the Patent Trial and Appeal Board End to End (“PTAB E2E”)
`
`1
`
`

`

`System. In addition, a copy of the Notice of Appeal, along with the required
`
`docketing fee, is being filed with the Clerk of Court for the United States Court of
`
`Appeals for the Federal Circuit.
`
`
`
`Dated: April 6, 2022
`
`Respectfully submitted,
`
`
`
`
`
`
`
`
`
`
`
`
`/s/ Cyrus A. Morton
`Cyrus A. Morton
`ROBINS KAPLAN LLP
`800 LaSalle Avenue, Suite 2800
`Minneapolis, MN 55402
`(612) 349-8500
`Attorney for Petitioners
`
`
`
`2
`
`

`

`CERTIFICATE OF SERVICE
`
`I hereby certify that on this April 6, 2022, a copy of Petitioners Medtronic,
`
`Inc. and Medtronic Vascular, Inc.’s Notice of Appeal Under 37 C.F.R. § 90.2(a)
`
`was served in its entirety by electronic mail on Patent Owner’s counsel at the
`
`following addresses included in Patent Owner’s Mandatory Notices:
`
`J. Derek Vandenburgh, Reg. No. 32,179
`dvandenburgh@carlsoncaspers.com
`
`Dennis C. Bremer, Reg. No. 40,528
`dbremer@carlsoncaspers.com
`
`Joseph W. Winkels
`jwinkels@carlsoncaspers.com
`
`Peter M. Kohlhepp
`pkohlhepp@carlsoncaspers.com
`
`Tara C. Norgard
`tnorgard@carlsoncaspers.com
`
`Megan E. Christner, Reg. No. 78,979
`mchristner@carlsoncaspers.com
`
`Shelleaha L. Jonas
`sjonas@carlsoncaspers.com
`
`
`Dated: April 6, 2022
`
`
`
`
`
`Respectfully submitted,
`/s/ Cyrus A. Morton
`Cyrus A. Morton
`Reg. No. 44,954
`Attorney for Petitioners
`
`
`
`3
`
`

`

`
`
`
`Exhibit A
`Exhibit A
`
`

`

`MEDTRONIC, INC., AND MEDTRONIC VASCULAR,INC.,
`Petitioner,
`
`V.
`
`TELEFLEX INNOVATIONS S.AR.L.,
`Patent Owner.
`
`IPR2020-01341
`Patent 8,142,413 B2
`
`Before SHERIDAN K. SNEDDEN, JAMES A. TARTAL,and
`CHRISTOPHER G. PAULRAJ, Administrative Patent Judges.
`
`TARTAL,Administrative Patent Judge.
`
`Trials@uspto.gov
`571-272-7822
`
`Paper No. 93
`Date: February 7, 2022
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`  ÿ
` ÿÿ
`  
`

` ÿ
` ÿ  ÿÿ ÿ
`ÿ
`!"#ÿ$%#$ÿ%#ÿ%ÿ&%#'%&(ÿ)"*#ÿ
`ÿ
`+#)&#ÿ,#ÿ%#ÿ&"%-ÿ%ÿ%#%-ÿ+)%&ÿ
`ÿ
`'#&)"*ÿ"* ÿ%ÿ'#&)"*ÿ.%$*!-%&ÿ"* ÿ
`  
`/ ÿ ÿ
`#-#-#0ÿ").%")$ÿ$ 1 & - ÿ
` / ÿ)2/ ÿ
`ÿ
`"&   3ÿ
` / ÿ33ÿ+ÿ
`ÿ
`+4
` ÿ$,#&"%ÿ( ÿ$##ÿ5%'#$ÿ% ÿ%&%-ÿ /6ÿÿÿÿÿÿ
`*,&"$),#&ÿ7 ÿ%!-&%5ÿ89:;<;=>?@>;ABÿD@>B<>ÿEF9GB=Hÿ
`%&%-ÿ89:;<;=>?@>;ABÿD@>B<>ÿEF9GB ÿÿ
`5!7'#ÿ
`/ ÿI  /ÿJ
`/ÿ
`
`  K//
ÿ
`ÿ*L /
6ÿ* Kÿ!/ / ÿ
`K/
ÿ  
`/ Mÿ'
` 
`/ÿ
`ÿ#NJ6ÿ
`OPÿQHRHSHÿTÿOUVW@Xÿ
`ÿ
`ÿ
`ÿ
`
`JUDGMENT
`Final Written Decision
`Determining No Challenged Claims Unpatentable
`Dismissing Petitioner’s Motion to Exclude
`35 U.S.C. § 318(a)
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`Wehavejurisdiction to conduct this inter partes review
`
`under 35 U.S.C. § 6. This Final Written Decision is issued pursuant
`
`to 35 U.S.C. § 318(a) (2018) and 37 C.F.R. § 42.73 (2019). For the reasons
`
`discussed below, we determine Medtronic, Inc. and Medtronic Vascular, Inc.
`
`(“Petitioner”)! has not shown by a preponderanceofthe evidencethat any of
`
`claims 1, 2, 4, 5, and 7-14 (“the Challenged Claims”) of U.S. Patent
`
`No.8,142,413 B2 (Ex. 1001, “the ’413 patent’’) are unpatentable.
`
`I.
`
`INTRODUCTION
`
`A. Summary ofProcedural History
`
`   ÿ
`
`
ÿ ÿ ÿ
`
ÿ
`
ÿ  ÿ ÿ  ÿ ÿ ÿ"# $ÿ

%ÿ
` 
ÿ&ÿ'()(*(ÿ+ÿ,(ÿÿ-ÿ.
`/ÿ
ÿ0
 ÿÿ
ÿ1
` ÿ
` ÿ&ÿ'()(*(ÿ+ÿ2
`3ÿ2 3ÿ
` ÿ4ÿ*(.((ÿ+ÿ (4ÿ2 53(ÿÿ.ÿ 
ÿ

` ÿ
`
ÿ6
/%ÿ%
ÿ
7
ÿ8
  ÿ (ÿ
` ÿ8
  ÿ9
`/
`ÿ (ÿ
`2:
 
;3ÿ
`ÿ  ÿ% ÿ6<ÿ
`ÿ1
1 

` 
ÿ=ÿ 
ÿ


ÿ 
` ÿ
` <ÿ=ÿ
`/
`7ÿÿ ÿÿ&ÿ
` ÿ4>ÿ2: 
ÿ*
`//
?
ÿ*/
`7;3ÿ=ÿ'()(ÿ
`
ÿ
`@(ÿ ÿ ÿ2AB(ÿÿ: 
ÿCÿ1
`
;3ÿ
`
ÿ 1
`

`6/
(ÿ
`(ÿ@-E0'*-E@ÿ
`FGÿIJKK# LÿMNÿO MPQJ #RÿS$M Lÿ
`
 
ÿ=/
ÿ
`ÿ
  ÿ1
` ÿ ÿ&ÿ'()(*(ÿ++ÿ>5ÿ
`
T
  ?ÿ
` ÿ ÿ"# $ÿ

%ÿ=ÿ 
ÿ*
`//
?
ÿ*/
`7(ÿÿ
`1
ÿÿ
`2:
(;3(ÿÿ
ÿ   
ÿ
` ÿ ÿ"# $ÿ

%ÿ=ÿ 
ÿ*
`//
?
ÿ*/
`7ÿ ÿ
`
`//ÿ? ÿ=ÿ 1
`

`6/ <ÿ
`

ÿ ÿ 
ÿ
  (ÿÿ
`1
ÿÿ2:  (ÿ
`0
(;3(ÿÿ-
/
=/
Bÿ 
`  ÿ)(U((V(ÿ2:
`
ÿE%
;3 ÿ=/
ÿ
`ÿ
`
ÿ
`E%
ÿ
1 
(ÿÿ
`1
ÿ ÿ2: Eÿ
1(;3ÿ2 
ÿ

`/3ÿ ÿ2

`
ÿ
`16//<ÿ
`
6/
3(ÿÿ
 
ÿ=/
ÿ
`ÿ
1/<ÿ ÿ 
ÿ
`
ÿE%
ÿ
1 
(ÿÿ
`
`1
ÿ&ÿ2:
(ÿ
1/<;3ÿ2 
ÿ

`/3ÿ& ÿ2

`
ÿ16//<ÿ
`
6/
3(ÿÿ
`ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ
`ÿ
 
ÿ
=
ÿ
`ÿ

`/ÿ1
` 
 

 ÿ8
  ÿ (ÿ
` ÿ
`8
  ÿ9
`/
`ÿ (ÿ
` ÿ
`
ÿ:8
  ÿ1/ÿÿ 
ÿ/ 7
`
ÿ1
`
ÿ=ÿ
`6 ÿ
 
(;ÿÿ
(ÿ(ÿÿÿ
` ÿ
`
ÿE%
ÿ
=
ÿ
`ÿ

`/ÿ1
` 
 

 ÿ-
/
=/
Bÿ8

`/ÿ0

ÿ
`)(U((V(Wÿ9
`/
`ÿ)/  ÿVV*WÿX%ÿ

` 
`/ÿ (Wÿ
` ÿ
`-
/
=/
BÿVV*(ÿÿ
`1
ÿ4ÿ (ÿÿ
`
ÿE%
ÿ
`/ÿ
`
ÿ:-
/
=/
Bÿ 1
`
ÿ
`ÿ 
ÿ/ 7
`
ÿ1
`
ÿ=ÿ 
ÿ
 
ÿ/
ÿ
`6
(;ÿÿYQGÿ
`ÿ ÿ ÿ     ÿ
`
ÿE%
ÿ=/
ÿ
`ÿ 
/7
`<ÿ
1 
ÿ ÿ 
ÿ
`
  ÿ

ÿ17
`/<ÿ ÿ%

ÿ

`<ÿ

`/ÿ=ÿ 
ÿ
  ÿ
`%
`ÿ%
`
`
ÿ  ÿ ÿ 
ÿ7
 ÿ=ÿ
 
Cÿ 1
`

`6/ <ÿ
 (ÿÿ
`Iÿ
`1
ÿ(ÿÿ
`
ÿE%
ÿ
`/ÿ=/
ÿ
`ÿ*  ?
ÿ8  ÿ ÿX7
ÿ
`2
`1
ÿ ,3ÿ%ÿ
`
ÿE%
ÿ6
T
/<ÿ% 
%ÿ2
`1
ÿ&,3(ÿÿ
` ÿ
`
`' Petitioner identifies as real parties-in-interest Medtronic, Inc. and
`Medtronic Vascular, Inc., and states, “Medtronic plc is the ultimate parent of
`both entities.” Pet. 4.
`? Patent Owneridentifies as real parties-in-interest Teleflex Medical Devices
`S.A.R.L.; Vascular Solutions LLC; Arrow International, Inc.; and
`Teleflex LLC. Paper 7, 2. Patent Owneralsostates, “Teleflex Incorporated
`is the ultimate parent of the entities listed above.” Jd.
`3 Prior to institution, Patent Ownerfiled a Preliminary Responseto the
`Petition directed primarily to whether discretionary denial of the Petition
`was warranted, not to the merits of Petitioner’s unpatentability contentions.
`See Paper 8. Patent Owneralso filed a Contingent Motion to Amend
`(Paper 26), which Patent Owner subsequently withdrew (Paper 56).
`
`Petitioner filed a Petition pursuant to 35 U.S.C. §§ 311-319
`
`requesting an inter partes review of the Challenged Claims. Paper 1
`
`(‘Pet.””). Weinstituted an inter partes review of the Challenged Claims on
`
`all grounds of unpatentability asserted in the Petition. Paper 11 (“Inst.
`Dec.”). Teleflex Innovations S.A.R.L. (“Patent Owner”)filed a Patent
`Owner Response.? Paper 23 (“PO Resp.”) (underseal), 24 (redacted,
`
`publicly accessible). Petitioner filed a Reply to the Patent Owner Response.
`
`Paper 51 (“Pet. Reply’) (under seal), 52 (redacted, publicly accessible).
`
`2
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`Patent Ownerfiled a Sur-reply in support of the Patent Owner Response.
`
`Paper 67 (“PO Sur-reply”).
`
`Following oral argument, we entered a transcript of the hearing in
`
`the record. Paper 92 (“Tr.”). Petitioner bears the burden of proving
`
`unpatentability of each claim it has challenged by a preponderanceof the
`
`evidence, and the burden of persuasion nevershifts to Patent Owner.
`
`See 35 U.S.C. § 316(e); 37 C.F.R. § 42.1(d); Dynamic Drinkware, LLC v.
`
`Nat’l Graphics, Inc., 800 F.3d 1375, 1378 (Fed. Cir. 2015).
`
`B. Related Proceedings
`
`Petitioner also challenges claims 1, 2, 4, 5, and 7—14 ofthe
`
`°413 patent under separate grounds in IPR2020-01342. Pet. 5—6; Paper7, 3.
`
`The ’413 patent also was the subject of a previous inter partes review in
`
`Boston Scientific Corp. and Boston Scientific Scimed, Inc., v. Vascular
`
`Solutions, Inc., 1PR2014-00759, which was terminated based on settlement
`
`and no final written decision was issued. IPR2014-00759, Paper 10, 2—3
`
`(PTAB August 11, 2014).
`
`The parties state the ’413 patent is a subject of Vascular
`
`Solutions LLC, et al. v. Medtronic, Inc., et al. No. 19-cv-01760 (D. Minn.
`
`   ÿ
`
`
ÿ ÿ ÿ
`
`
ÿ
ÿ
ÿ
`ÿ
ÿ ÿ ÿÿ 
ÿ
`
ÿ
ÿ
 
ÿÿ
`
`
ÿ !ÿ"# ÿ
$%ÿÿÿ
`& 'ÿ
`ÿ
`'(
ÿ
ÿ

ÿ
`ÿ 
` ) ÿÿ 
ÿ

` 'ÿ ÿ
`
` 
ÿ
)ÿÿ
`
ÿ* ÿ"#+$%ÿÿ
 
ÿ,

`ÿ 
ÿ,
ÿÿ- 'ÿ
` 
`

`, ÿÿ

`)ÿ)
`(ÿ ÿ
`ÿ)
`
'
ÿ,ÿ
`ÿ
 

` )
ÿÿ 
ÿ
`
-
)
ÿ
` ÿ 
ÿ,
ÿÿ

` ÿ
-
ÿ ÿ ÿ
`
ÿ
ÿÿ
`.//ÿ0ÿ12ÿ3ÿ "
%4ÿ!ÿ2&ÿ3ÿ "%4ÿ56789:;ÿ5=:7>?8=/@ÿAABÿCDÿ
`E8FGHÿI=8JK:;L@ÿM7;ÿÿ&ÿ!0ÿ!ÿ"&
ÿ2ÿ 0%ÿ
`NDÿP/H8F/QÿR=S;//Q:7TLÿ
`
 
ÿ
`ÿ)
`
'
ÿ)
`(ÿÿ ÿÿ0ÿ
` ÿ!Uÿÿ 
ÿ
`Vÿ
`
ÿ 
ÿ

`
`
ÿ' ÿ ÿ    ÿÿ
ÿ0U 4ÿ
`
ÿ!ÿÿÿ
`+
ÿVÿ
`
ÿ
`ÿ
`ÿ 
ÿ,W
) ÿÿ
`ÿ
-ÿ:7F/=ÿJ8=F/Lÿ
-
ÿ ÿ
`NSLFS7ÿ.;:/7F:X:;ÿBS=JDÿ87QÿNSLFS7ÿ.;:/7F:X:;ÿ.;:9/Q@ÿM7;DÿCDÿY8L;ZH8=ÿ
`.SHZF:S7L@ÿM7;Dÿ  !0*ÿ)ÿ
`ÿ
(
`
ÿ,
`
ÿ ÿ

(
ÿ
`
` ÿ ÿ
`ÿ
ÿ
) ÿ
`ÿ
ÿÿ  !0*ÿ
`
ÿÿ Uÿ
`" +[ÿ[' ÿÿ %ÿÿÿ
`+
ÿ
` 
ÿ
`
ÿ 
ÿVÿ
`
ÿÿ
`ÿ,W
) ÿÿY8L;ZH8=ÿ
`.SHZF:S7LÿAAB@ÿ/Fÿ8HDÿCDÿ\/QF=S7:;@ÿM7;D@ÿ/Fÿ8HDÿ]ÿ*)-! ÿ"^ÿ_ ÿ
`
ÿ`ÿ ÿ *%ÿ
` ÿab\/Q:;8H@ÿAABÿCDÿY8L;ZH8=ÿ.SHZF:S7L@ÿAABÿ]ÿ!
`)-* *ÿ"^ÿ_ ÿ
ÿ`
ÿÿ !%ÿÿ
ÿU04ÿ
`
ÿ!ÿ ÿÿ
`
ÿ
ÿ
` )
`
ÿ 
` ÿ, ÿÿ 

ÿ ) ÿ) ÿ)
 'ÿ)
ÿ
`
ÿ
`
ÿÿ
`
`
ÿ!ÿ ÿ[ 
`ÿ
 
ÿ
ÿ
  ÿ)
`
' 'ÿ
`
ÿ

`
ÿ ÿ
` 
ÿVÿ
`
ÿ ÿ 
ÿ 'ÿ)
 'cÿ    ÿ
` ÿ   
`
` !ÿ"
`
ÿ ÿ %4ÿ    ÿ    *ÿ   
`ÿ
` ÿ   ÿ"
`
ÿd0ÿd%4ÿ    ÿ
`   ÿ
` ÿ   ÿ"
`
ÿd0! ÿd%4ÿ   0ÿ
`ÿ
`
`filed July 2, 2019) and OXMedical, LLC v. Vascular Solutions, LLC, No. 17-
`
`cv-01969 (D. Minn.filed June 8, 2017). Pet. 4-5; Paper 7, 2. Patent Owner
`
`indicates that both of these district court proceedings currently are stayed.
`
`Paper7, 2.
`
`Additionally, Petitioner filed petitions challenging patents related to
`
`the ’413 patent in the following proceedings: IPR2020-00126 and IPR2020-
`
`00127 (Patent 8,048,032 B2); IPR2020-00128, IPR2020-00129, IPR2020-
`
`00130, and IPR2020-00131 (Patent RE45,380 E); IPR2020-00132,
`
`IPR2020-00133, and IPR2020-00134 (Patent RE45,760 E); IPR2020-00135
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`and IPR2020-00136 (Patent RE45,776 E); IPR2020-00137 and IPR2020-
`
`00138 (Patent RE47,379 E); and IPR2021-01343 and IPR2021-01344
`
`(Patent RE46,116 E). Institution of inter partes review was denied in
`
`IPR2020-00131 and IPR2020-00133. Final written decisions are pending in
`
`IPR2021-01343 and IPR2021-01344. In the remaining listed proceedings,
`
`final written decisions were entered determining that a preponderance ofthe
`
`evidence did not show any claim challenged was unpatentable.
`
`C. The ’413 Patent
`
`The 413 patent, titled “Coaxial Guide Catheter for Interventional
`
`Cardiology Procedures,” issued on March 27, 2012, from a non-provisional
`
`application filed June 28, 2010. Ex. 1001, codes (45), (54), (22). The ’413
`
`patent relates generally to a coaxial guide catheter for use with interventional
`
`cardiology devices that are insertable into a branch artery that branches off
`
`   ÿ
`
`
ÿ ÿ ÿ
`
` ÿ   ÿ
`
ÿÿÿ   ÿ
` ÿ   
`ÿ
`
ÿÿÿ
` ÿ   ÿ
` ÿ   ÿ
`
`
ÿÿÿÿ     ÿÿ !"#$ÿ&'$"#(ÿ)
*
+ÿ+
`ÿ

ÿ ÿ
`   ÿ
` ÿ   ÿÿ,
`-ÿ+)
ÿ
. ÿ
`)
ÿ/
 0ÿ ÿ
`   ÿ
` ÿ   ÿÿ ÿ 1
ÿ)
2
`  0ÿ-
ÿ/).
 0ÿ
`
`
`-ÿ+)
ÿ
. ÿ+
)
ÿ
)
ÿ
)2  0ÿ 1
` ÿ
`ÿ/)
/ 
)
` .
ÿÿ 1
ÿ
`
*
.
ÿÿ  ÿ1+ÿ
` 3ÿ.-
`2ÿ.1
`--
0
ÿ+
`ÿ /
`

`4-
ÿ
`56ÿ89#ÿ:;<=ÿ>'"#!"ÿ
`?1
ÿ@ÿ/
`
ÿ  -
ÿAB
`C
`-ÿD
ÿB
` 1
)ÿ)ÿ
)*

`-ÿ
`B
`)-03ÿ ).
)
Eÿ
ÿ ÿF
`).1ÿ ÿ  ÿ)2ÿ
`ÿ  /)*
`-ÿ
`
`//-.
`  ÿ-
ÿG
ÿ ÿ ÿÿCÿÿ.
ÿÿÿ ÿÿ?1
ÿ@ÿ
`/
`
ÿ)
-
`
ÿ0
)
`--3ÿ ÿ
`ÿ.
`C
`-ÿ0
ÿ.
` 1
)ÿ)ÿ
ÿ+ 1ÿ
)*

`-ÿ
`.
`)-03ÿ
*.
ÿ 1
` ÿ
`)
ÿ 
)
`4-
ÿ ÿ
`ÿ4)
` .1ÿ
`)
)3ÿ 1
` ÿ4)
` .1
ÿÿ
`)2ÿ
`ÿ2
` ÿ
`)
)3ÿÿCÿÿH4 )
`. ÿÿÿ
`H..) 0ÿ ÿ 1
ÿ@ÿ/
`
ÿ
)*

`-ÿ.
`)-03ÿ/).
)
ÿ
`
ÿ .-
ÿ 
)  0ÿ0
+)
ÿ)ÿ 1
)ÿ  )2
ÿ 1)01ÿ.
` 1
)ÿ
`
` ÿ.)
`)3ÿ
`)
)
ÿ 1
` ÿ4)
` .1ÿÿ)2ÿ 1
ÿ
`)
`ÿÿIJ6ÿ
` ÿK L ÿÿ
` ÿ.)
`)3ÿ
`)
)3ÿ

`
ÿ
` 1
).-
) .ÿ/-
`M
ÿ)ÿ 1
)ÿ-
 ÿ2
`3ÿ
`
`))+ÿ)ÿ..-
ÿ 1
ÿ.)
`)3ÿ
`)
)
ÿÿIJ6ÿ
` ÿK Lÿÿ?1
ÿ@ÿ/
`
ÿ
`
`
`
ÿ 1
` ÿAN O
`))+ 0ÿÿ)

))
ÿ ÿ
`ÿ
EÿÿIJ6ÿ
` ÿKLÿÿ
`A ÿ )

`  0ÿ
`ÿ
ÿ
`ÿ0
ÿ.
` 1
)ÿÿ 3/.
`--3ÿ 
)
ÿ 1)01ÿ 1
ÿ
`)
`ÿ
`
` ÿ ÿ 1
ÿ 2ÿÿ 1
ÿ.)
`)3ÿ
`)
)3Eÿ2
2
ÿ+ 1ÿ 1
ÿ
`ÿÿ
`ÿ
`0
+)
ÿÿIJ6ÿ
` ÿKLÿÿ?1
ÿ@ÿ/
`
ÿ) 1
)ÿ
`
ÿ
`ÿ--+Kÿÿÿ
`Hÿ0
ÿ.
` 1
)ÿÿ 3/.
`--3ÿ

`
ÿ ÿ 1
ÿ/
 0ÿ)ÿ 2ÿÿ
` 1
ÿ
`)
)3ÿ ÿ4
ÿ )

`
ÿ
` ÿ
`ÿ0
+)
ÿ)ÿ 1
)ÿ  )2
ÿÿ
`/
`
ÿ 1)01ÿ 1
ÿ-2
ÿÿ 1
ÿ0
ÿ.
` 1
)ÿ
` ÿ 
)
ÿ ÿ
` 1
ÿ
`)
)3ÿ4
3 ÿ 1
ÿ..- ÿ)ÿ
ÿÿB) 0ÿ 01ÿ
`-
 ÿ.
` ÿ.)

`
ÿ
01ÿ4
`.P+
`)ÿ).
ÿ ÿ-0
ÿ 1
ÿ0
ÿ
`ÿ
`
`A guide catheter is typically seated into the opening or ostium of
`the artery to be treated and a guidewire or other instrumentis
`passed through the lumen of the guide catheter and inserted into
`the artery beyond the occlusion or stenosis. Crossing tough
`lesions can create enough backward force to dislodge the guide
`
`from a main artery. Ex. 1001, Abstract.
`
`According to the ’413 patent, interventional cardiology procedures
`
`often include inserting guidewires or other instruments through catheters
`
`into coronary arteries that branch off from the aorta. Jd. at 1:21-23.
`
`In coronary artery disease, atherosclerotic plaques or other lesions may
`
`narrow or occlude the coronary arteries. Jd. at 1:26—30. The ’413 patent
`
`states that “[n]arrowingis referred to as stenosis.” Jd. at 1:30—31.
`
`“In treating a stenosis, a guide catheteris typically inserted through the aorta
`
`and into the ostium of the coronary artery,” sometimeswith the aid of a
`
`guidewire. Id. at 1:35—37. The ’413 patent further states as follows:
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`catheter from the ostium of the artery being treated. This can
`makeit difficult or impossible for the interventional cardiologist
`to treat certain forms of coronary artery disease.
`
`Id. at 1:37-45. The ’413 patent discusses “four categories” of “[p]rior
`
`attempts to provide support to the guiding catheter to prevent backward
`
`dislodgement from the coronary ostium (referred to as ‘backup support’),”
`
`consisting of: (1) “guiding catheters that, through a combination of shape
`
`and stiffness, are configured to draw backup support from engaging the wall
`
`of the aortic arch;” (2) “guiding catheters that include a retractable
`
`appendage;” (3) guide catheters that have apportion that seeks to expand
`
`laterally;” and, (4) “placement of a smaller guide catheter within a larger
`
`guide catheter in order to provide add support.” Jd. at 1:46-2:39. The
`
`’413 patent identifies various deficiencies with these prior attempts,
`
`including an increased risk of damageto the aortic wall and mechanical
`
`complexity. See id. Specifically, with regard to the fourth category of prior
`
`attempts, the ’413 patent states as follows:
`
`   ÿ
`
`
ÿ ÿ ÿ
`
` 
ÿÿ 
ÿ ÿÿ 
ÿ
`
ÿ
 ÿ 

`
ÿÿ ÿ
` ÿ
`
`!
ÿ ÿ" ÿÿ#"
ÿÿ 
ÿ
$

`"ÿ
`" ÿ
` ÿ 

` ÿ

` ÿÿÿ
`ÿ
`
ÿ

`
ÿ
`%&'ÿ
` ÿ()*ÿÿ 
ÿ+ÿ#
`
ÿ
ÿ,ÿ
`

-ÿÿ,.#/ÿ
`
`
# ÿ ÿ#$
ÿ## ÿ ÿ 
ÿ ÿ
` 
ÿ ÿ#
$
ÿ
`!0
`ÿ
`
`"

ÿÿ 
ÿ
`ÿ ÿ1


ÿ ÿ
`ÿ2
`!#ÿ## +3-ÿ
`   ÿ(ÿ13ÿ, ÿ
` 
ÿ 
` ÿ ÿ
`ÿ
`  ÿÿ
`#
ÿ
`
`
` ÿ 
ÿ
`
ÿ 
ÿ ÿ
`0ÿ
`!#ÿ## ÿÿ

` ÿ 
ÿ0
`""ÿ
`ÿ 
ÿ
` ÿ
`4-ÿ1 3ÿ, ÿ
` 
ÿ 
` ÿ "
ÿ
`ÿ

`
`"
ÿ
`
`##

`
4-ÿ13ÿ
ÿ
` 
ÿ 
` ÿ
`$
ÿ
`##  ÿ 
` ÿ
!ÿ ÿ
5#
` ÿ
`"
`

`""4-ÿ
` ÿ13ÿ,#"
`

ÿÿ
`ÿ
`""
ÿ
ÿ
` 
ÿ0  ÿ
`ÿ"
`
ÿ
`
ÿ
` 
ÿ ÿ
ÿ ÿ#$
ÿ
`ÿ## -ÿÿ%&'ÿ
` ÿ(6* (7ÿÿ 
ÿ
`+ÿ#
`
ÿ

ÿ$
`ÿ


ÿ0 ÿ 

ÿ#ÿ
`
# ÿ
` " ÿ
` ÿ 

`
ÿ!ÿÿ
`
`
ÿ ÿ 
ÿ
` ÿ0
`""ÿ
` ÿ

` 
`"ÿ
`#"
5 ÿÿ899ÿ;&'ÿ<#

`""ÿ0 ÿ

`ÿ ÿ 
ÿ ÿ
`
ÿÿ#ÿ
`
`
# ÿ 
ÿ+ÿ#
`
ÿ
`
ÿ
`ÿ""0(ÿ
` ÿ
 =
ÿÿ
ÿ ÿ
ÿ ÿ#$
ÿ
`ÿ
ÿÿ
#ÿ
`

`  ÿ 
ÿ
ÿ
` 
ÿ0  ÿ 
ÿ ÿÿ 
ÿ
`ÿ
`
`
ÿÿ>
#ÿ

`  ÿ

ÿ ÿ 
  ÿ 
ÿ
` 
ÿ
ÿ
#"ÿ
` ÿ 
ÿ ÿÿ 
ÿ
`ÿ
`
ÿ 
` ÿ #
`""ÿ
`ÿ
ÿ
`
ÿ

ÿÿ?  
`
"ÿ
#ÿ

`  ÿÿ ÿ
 =
ÿ0 ÿ
`
`ÿ "ÿ
`$
`"
`"
ÿ
ÿ
` 
ÿ

`
ÿ 
ÿ!ÿ 
` ÿ 
ÿ
`
"
` $
"ÿ ÿ5
ÿ$
ÿ
ÿ
` 
ÿ0""ÿ
`
`
ÿ 
ÿ
`
`ÿ
`
ÿÿ ÿ
`
`
ÿ
`ÿ"

`ÿ ÿ
  ÿÿ 
ÿ
`
`ÿ
`
ÿ0
ÿ 
ÿ
` 
ÿÿ
`$
` 
ÿ#
` ÿ 
ÿ ÿ
`<
$

`"ÿ 
ÿ#"
ÿ
`
ÿ0
ÿ ÿ
`ÿ
` 
`ÿ
ÿ
`
` 
ÿ ÿ ÿ
` 
 
`
` 
ÿ
` ÿ@ ÿ 
ÿ
ÿ
`
` 
ÿ ÿ
ÿ
` 
`""ÿ" 
ÿ 
` ÿ 
ÿ
ÿ 
ÿ
`

ÿ
ÿ
` 
ÿ<
 ÿ
`ÿ
0ÿ

`ÿ$
`"$
ÿ ÿ
`
ÿ#"
`
ÿ ÿ 
ÿ
ÿ
ÿ
` 
ÿ0ÿ#
$
ÿ 
ÿ"
`
ÿ
`
`
ÿ
` 
ÿÿ
 ÿ
ÿÿ 
` ÿ A
  ÿÿ#

ÿ
`

`

ÿ ÿ 
ÿ
`""
ÿ
ÿ
` 
ÿ ""ÿ ÿ
ÿ
` 

ÿ ÿ 
ÿ
`ÿ$

"ÿ0 ÿ

` ÿ
`
ÿ 
ÿ 
ÿ
`""
ÿ
`ÿ
`
`This technique is used in order to provide a method of deep
`seating the guide catheter within the ostium of the coronary
`artery. Deep seating refers to inserting the catheter more deeply
`into the ostium of the coronary artery than typically has been
`done before. Unfortunately, deep seating by this technique with
`a commonly available guide catheter creates the risk that the
`relatively stiff, fixed curve, guide catheter will damage the
`coronary artery. This damage may lead to dissection of the
`coronary artery when the catheter is advanced past the ostium.
`Several other problems arise when using a standard guide
`catheter in this catheter-in-a-catheter fashion. First, the inner
`catheters must be substantially longer than the one hundred
`centimeter guide catheter. Second, a new hemostasis valve must
`be placed on the inner guide catheter which prevents the larger
`guide catheter from being used for contrast injections or pressure
`measurements. Third, the smaller guide catheter still must be
`inserted into the coronary vessel with great care since the smaller
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`Id. at 2:30-S0. The ’413 patent states “a system that would be deliverable
`
`through standard guide catheters for providing backup support by providing
`
`the ability to effectively create deep seating in the ostium of the coronary
`
`artery” would be beneficial to “the interventional cardiology art.” Jd.
`
`at 2:51-55.
`
`The ’413 patent describes “a coaxial guide catheter that is deliverable
`
`through standard catheters by utilizing a guidewire rail segment to permit
`
`delivery without blocking use of the guide catheter.” Jd. at 2:59-62. “The
`
`coaxial guide catheter preferably includes a tapered inner catheter that runs
`
`over a standard 0.014 inch coronary guidewire to allow atraumatic
`
`placementwithin the coronary artery,” allowing “removal of the tapered
`
`inner catheter after the coaxial guide catheter is in place.” Jd. at 2:62—67.
`
`Figures 1 and 2, reproduced below, show a coaxial guide catheter and a
`
`tapered inner catheter as described in the ’413 patent:
`
`rd
`
`Fig. 1
`10
`
`guide catheter has no tapered transition or dilator at its tip and
`does not run over a standard 0.014 inch guidewire.
`
`   ÿ
`
`
ÿ ÿ ÿ
`
ÿ
` 
ÿ
`ÿ ÿ
`

ÿ 
`   ÿÿ
` ÿ
` ÿ ÿ ÿ
` ÿ
`
ÿ  ÿ ÿ
ÿ
`ÿ
` 
`ÿÿ ÿ

ÿ
` !"ÿ
` ÿ #$%ÿÿ&
ÿ'ÿ
`
ÿ
`
ÿ(
`ÿ)
*ÿ 
` ÿÿ+
ÿ


`+
ÿ
` ÿ
` 
`ÿ
ÿ
` 
ÿ,ÿ ÿ+
`-ÿ ÿ+)ÿ ÿ
` 
ÿ
`+ )ÿ ÿ
,,
 
)ÿ

`
ÿ
ÿ

`  ÿ ÿ 
ÿ *ÿ,ÿ 
ÿ
`)ÿ
`
`
).ÿÿ+
ÿ+
,
`ÿ ÿ( 
ÿ


`ÿ
`)ÿ
` .ÿÿ !"ÿ
`
` ÿ #%$%%ÿ&
ÿ'ÿ
`
ÿ
+
ÿ(
`ÿ
`/
`ÿ
ÿ
` 
ÿ 
` ÿÿ


`+
ÿ
` ÿ
` 
`ÿ
` 
ÿ+)ÿ 0 ÿ
`ÿ

ÿ
`ÿ
*
ÿ ÿ
* ÿ
`

)ÿ  ÿ+- ÿ
ÿ,ÿ 
ÿ
ÿ
` 
.ÿÿ !"ÿ
` ÿ #%1$ ÿÿ(&
ÿ
`
`/
`ÿ
ÿ
` 
ÿ
,

`+)ÿ 
ÿ
`ÿ
`

ÿ
ÿ
` 
ÿ 
` ÿ ÿ
`
ÿ
`ÿ
` 
`ÿÿ ÿ
`)ÿ

ÿ ÿ
`ÿ
` 
`*
` ÿ
`
`
*
ÿ  ÿ 
ÿ
`)ÿ
`
).ÿ
` ÿ(
*
`ÿ,ÿ 
ÿ
`

ÿ
`
ÿ
` 
ÿ
`,
ÿ 
ÿ
`/
`ÿ
ÿ
` 
ÿÿ ÿ
`
.ÿÿ !"ÿ
` ÿ # $2ÿÿ
`3
ÿÿ
` ÿ ÿ

ÿ+
ÿÿ
`ÿ
`/
`ÿ
ÿ
` 
ÿ
` ÿ
`ÿ
`
`

ÿ
ÿ
` 
ÿ
`ÿ
+
ÿ ÿ 
ÿ'ÿ
`
#ÿ
`ÿ
`3
ÿÿ
 ÿ
`

ÿ
ÿ
` 
ÿÿ

`
`
ÿ
` ÿ
`+
ÿ
`/
`ÿ
ÿ
`
` 
ÿ ÿ
` ÿ3
ÿ ÿ
 ÿ
`/
`ÿ
ÿ
` 
ÿ ÿ
` ÿ
`

ÿ
ÿ
`
` 
ÿÿ
`
*+
ÿ
`ÿ
`/
`ÿ
ÿ
` 
ÿ
`
*+)ÿÿÿ !"ÿ
` ÿ%# $ 2ÿ
`ÿ
`
`—10
` x 1a
`
`
`
`Figure 1 depicts tapered inner catheter 14 separate and above coaxial guide
`
`catheter 12, and Figure 2 depicts coaxial guide catheter 12 and tapered inner
`
`catheter 14 assembled as coaxial guide catheter assembly 10. Jd. at 5:22—27,
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`6:12—14; Figs. 1 and 2. Coaxial guide catheter 12 includestip portion 16,
`
`reinforced portion 18, and rigid portion 20. Jd. at 6:15—16. Tip portion 16
`
`generally includes bump tip 22 and marker band 24. Jd. at 6:20-21. Bump
`
`tip 22 includes taper 26 andis relatively flexible. Jd. at 6:21. Marker
`
`band 24 is formed of a radiopaque material such as platinum/iridium alloy.
`
`Id. at 6:25—26. Tapered inner catheter tip 42 includes tapered portion 46 at a
`
`distal end thereof, and straight portion 48. Jd. at 6:65-66. Both tapered
`
`portion 46 andstraight portion 48 are pierced by lumen 50 (not labeled in
`
`figures above). Jd. at 6:65-67. Tapered inner catheter 14 may also include
`
`clip 54 at a proximal end thereofto releasably join tapered inner catheter 14
`
`to coaxial guide catheter 12. Jd. at 7:3—S.
`
`Figures 8 and 9 of the ’413 patent are reproduced below.
`
`Fig. 8
`
`   ÿ
`
`
ÿ ÿ ÿ
` ÿÿÿ
` ÿ ÿÿ
`
`ÿ 
ÿ!
` "
#ÿ ÿ ! 
ÿ $ÿ$#  ÿÿ
`#
 %#!
ÿ$#  ÿÿ
` ÿ#ÿ$#  ÿ ÿÿ&'(ÿ
` ÿ)ÿÿ*$ÿ$#  ÿÿ
`
#
`+ÿ ! 
ÿ, -$ÿ $ÿ ÿ
` ÿ-
`#.
#ÿ,
` ÿ ÿÿ&'(ÿ
` ÿ  ÿÿ -$ÿ
` $ÿ ÿ ! 
ÿ
`$
#ÿ ÿ
` ÿÿ#

` /
+ÿ%
,
ÿÿ&'(ÿ
` ÿ ÿÿ0
`#.
#ÿ
`,
` ÿ ÿÿ%#-
ÿ%ÿ
`ÿ#
`$
`1
ÿ-
`
#
`ÿ !"ÿ
`ÿ$
`  -2# -ÿ
`+ÿÿ
`&'(ÿ
` ÿ ) ÿÿ*
`$
#
ÿ
#ÿ!
` "
#ÿ $ÿ ÿ ! 
ÿ
`$
#
ÿ$#  ÿÿ
` ÿ
`ÿ
`
`ÿ
ÿ "
#
%ÿ
` ÿ #
`" ÿ$#  ÿÿÿ&'(ÿ
` ÿ)ÿÿ "ÿ
`$
#
ÿ
`$#  ÿÿ
` ÿ #
`" ÿ$#  ÿÿ
`#
ÿ$
#!
ÿ,+ÿ -
ÿ)ÿ3  ÿ
`,

ÿ ÿ
`% #
ÿ
`,/
4ÿÿ&'(ÿ
` ÿ)ÿÿ*
`$
#
ÿ
#ÿ!
` "
#ÿÿ-
`+ÿ
`ÿ ! 
ÿ
`!$ÿ)ÿ
` ÿ
`ÿ$#-
`ÿ
ÿ "
#
%ÿ ÿ#


`
`,+ÿ5 ÿ
`$
#
ÿ
#ÿ!
` "
#ÿÿ
`
` ÿ!
`
`ÿ 
ÿ!
` "
#ÿ ÿÿ&'(ÿ
` ÿ)ÿ
`ÿ #
ÿÿ
` ÿ6ÿ%ÿ "
ÿ7ÿ$
`
ÿ
`#
ÿ#
$# !
ÿ,
8ÿ
`Fig. 9
`ÿ
` #
ÿÿ
` ÿ6ÿ
`#
ÿ!"
-
` !ÿ  #
`  ÿ%ÿ 
ÿ!
` "
#ÿ)ÿ8 "ÿ!
`
`ÿ
` 
ÿ!
` "
#ÿ ÿ 
#
ÿ ÿ  -ÿÿ%ÿ!#
`#+ÿ
`#
#+ÿ ÿÿ&'(ÿ
` ÿ)
`6ÿ)))ÿÿÿ*"
ÿ!
` "
#ÿ
`
-,+ÿ%ÿ #
ÿÿ ! 
ÿ$ 
`ÿ
`
`$
#
ÿ
#ÿ!
` "
#ÿÿ8"
#

`ÿ "
ÿ
`$$
`#
` ÿ%ÿ #
ÿ6ÿ
ÿ  ÿÿ&'(ÿ
`ÿ
`
`guide catheter 12 inserted into ostium 60 of coronary artery 62. Jd. at 5:43-
`
`Figures 8 and 9 are schematic illustrations of guide catheter 56 with coaxial
`
`49, 7:53-55, 7:67—8:4. The catheter assembly of Figure 8 includesoptional
`
`tapered inner catheter 14, whereas the apparatus of Figure 9 does not. Jd.
`
`

`

`catheter 56 and coaxial guide catheter 56” and “stiffer back up support than
`
`guide catheter 56 alone.” Jd. at 7:67—8:6. The 413 patent describes in
`
`detail a method of use, as follows:
`
`IPR2020-01341
`Patent 8,142,413 B2
`
`The ’413 patent states “the presence of coaxial guide catheter 12
`
`within guide catheter 56” provides “improved distal anchoring of guide
`
`   ÿ
`
`
ÿ ÿ ÿ
`
ÿÿ
`
ÿ
`
ÿ 
ÿ


ÿÿ
`
`ÿ
ÿ
` 
ÿ ÿ
`!  ÿ
ÿ
` 
ÿ"#$ÿ%
ÿ&%
ÿ 
`ÿ
`  ÿÿ
ÿ
`
` 
ÿ"#ÿ
` ÿ
`
`ÿ
ÿ
` 
ÿ"#$ÿ
` ÿ 
ÿ'
`(ÿÿ ÿ 
` ÿ
`
`
ÿ
` 
ÿ"#ÿ
`
)$ÿÿ*+,ÿ
` ÿ-.#-/.#)ÿÿ
ÿÿ
`
ÿ
'
ÿ ÿ
`

`ÿ
`ÿ&
 ÿÿ
ÿ
`ÿ!.ÿ
` ÿ

`  ÿ
`ÿ
ÿ
` 
ÿ"#ÿÿ 

ÿ ÿ
`ÿ&
`0ÿ' ÿ
`%

ÿ ÿ 
ÿ' 1ÿÿ
`ÿ
` ÿ
`ÿ"ÿ%
ÿ
!
ÿ#ÿ
` ÿ
` 
ÿ 
`ÿ
ÿ#ÿÿ
ÿ
` 
ÿ"#ÿÿ' ÿ ÿ& 1ÿ
`ÿ &ÿ#ÿÿ
`ÿ&
`
ÿ'
` ÿ' ÿ%

ÿÿ
`ÿ
`1ÿ
`
`
1ÿ# ÿ 
` ÿ ÿÿ

ÿ ÿ
)ÿ2
`
`ÿ
ÿ
` 
ÿ ÿ
`! ÿ
`

ÿ
ÿ
` 
ÿÿÿ 

ÿ ÿ
ÿ
`
` 
ÿ"#ÿ
` ÿ%
ÿ
!
ÿ#)ÿ3
ÿ
` 
ÿ"#ÿ
`
`
!
ÿ#ÿ
`
`ÿ
ÿ
` 
ÿ ÿ
` ÿ
`

ÿ
ÿ
`
` 
ÿÿ
`
ÿ&
` 
`
ÿ ÿ 
 ÿ
`

ÿ
ÿ
` 
ÿ ÿ ÿ
`
` ÿ 
ÿ &ÿ#ÿÿ 
ÿ' ÿ%

ÿ 
` ÿ'
` 
ÿÿ&ÿ 
ÿ
`&
`0ÿ' ÿ%

)ÿ
ÿ'&ÿ ÿ ÿÿ
`
`ÿ
ÿ
` 
ÿ ÿ
`ÿ 

ÿ! ÿ
`

ÿ
ÿ
` 
ÿ ÿ ÿ!
ÿ ÿ &ÿ#ÿ
`ÿ
`1ÿ
`
1ÿ# ÿÿ 
ÿ' ÿ%

ÿ ÿ'&ÿ ÿ ÿÿ
`
`
`ÿ
ÿ
` 
ÿ ÿ
`
%
ÿ
`ÿ
ÿ

`
ÿ  )ÿ
`
`

ÿ
ÿ
` 
ÿÿÿ 
ÿ!  
`! ÿ&ÿ 
ÿ&
ÿÿ
`
`
`ÿ
ÿ
` 
ÿ )ÿÿ4 ÿ
%

`ÿ
` 1ÿ
` 

` &
ÿ
%
ÿÿ
`ÿ
`ÿ
` 
ÿ'

` ÿ
`ÿ
ÿÿ
`ÿ'
` ÿ
`5  ÿ! 6ÿÿ 
ÿ 

ÿ ÿ 
ÿ&
ÿÿ
`
`ÿ
ÿ
`
` 
ÿ ÿ!ÿ
&
` ÿ 
ÿ
ÿ
` 
ÿ"#)ÿ
`7
ÿ 
ÿ
%

`ÿ
` 1ÿ
%
ÿ

`
ÿ
`ÿ
ÿÿ
`ÿ'(
`
ÿ ÿ
`1ÿ
`
1ÿ# ÿÿ
`  
ÿ'
` ÿ' ÿ%

ÿ
`
ÿ&
`1ÿ'
ÿ
`
ÿ ÿ 
ÿ
%

`ÿ
` 1ÿ
%
ÿ
`
` 
ÿ!
ÿ
 
ÿ  ÿÿ
` ÿ ÿ  ÿ ÿÿ
`
`
`ÿ
ÿ
` 
ÿ ÿ%
ÿ'
`(ÿÿ )ÿÿ
ÿ'
`(ÿ
`
ÿ 
` ÿ! ÿ
ÿ ÿ  
ÿ'&ÿ ÿ ÿ&ÿ
`ÿ
ÿ

`
ÿ
`  ÿ ÿ 
ÿ &ÿ ÿ 
ÿ'
` ÿ' ÿ%

ÿÿ 
` 

ÿ
` ÿ
 
ÿ  ÿÿ ÿ ÿ  ÿ ÿÿ
`
`ÿ
ÿ
`
` 
ÿ )ÿ4ÿ1
` ÿ&
`1ÿ
`1ÿ
`ÿ
ÿ ÿ 
ÿ&
`ÿ
ÿ
`ÿ 
ÿ
`
`ÿ
ÿ
` 
ÿ ÿ ÿ
 ÿ   ÿÿ'&ÿ
` ÿ ÿ&ÿ 
ÿ &ÿÿ 
ÿ'
` ÿ
`
1)ÿ
`ÿ
`
`In operation, a guide catheter 56 is inserted into a major blood
`vessel in the body such as aortic arch 58 over guidewire 64 and
`the distal end 68 of guide catheter 56 is brought into proximity
`of ostium 60 of a smaller branch blood vessel, such as coronary
`artery 62, that it is desired to enter. Coaxial guide catheter 12,
`with tapered inner catheter 14,
`is inserted through guide
`catheter56 and over guidewire 64. Guide
`catheter 56,
`guidewire 64, coaxial guide catheter 12, and tapered inner
`catheter 14 are manipulatedto insert tapered inner catheter tip 42
`into the ostium 60 of the blood vessel that branches off from the
`major blood vessel. The bumptip 22 of coaxial guide catheter 12
`is inserted with tapered inner catheter tip 42 well into ostium 60
`of coronary artery 62 or other blood vessel until bump tip 22 of
`coaxial guide catheter 12 achieves a deep seated position.
`Tapered inner catheter 14 is then withdrawn from the lumen of
`coaxial guide catheter 12.
`An interventional cardiology
`treatment device such as a catheter bearing a stent or a balloon
`(not shown)is then inserted through the lumen of coaxial guide
`catheter 12 which remains inside guide catheter 56.
`Whentheinterventional cardiology device reachesa steno sis
`or blockage in coronary artery 62 or another branch bloodvessel,
`force may be applied to the interventional cardiology device
`catheter while reinforced portion 18 and rigid portion 20 of
`coaxial guide catheter 12 provide back up support. The back
`force that would tend to dislodge bumptip 22 from a deep seated
`position in the ostium in the branch blood vessel is transferred
`through reinforced portion 18 to rigid portion 20 of coaxial guide
`catheter 12. A physician may apply a force to the proximal end
`of the coaxial guide catheter 12 to resist dislodging of bump
`tip 22 from the ostium ofthe branchartery.
`
`

`

`IPR2020-01341
`Patent 8,142,413 B2
`
`Id. at 9:51-10:15; see also id. at 1:23—26(stating that “the term
`
`‘interventional cardiology devices’ is to be understoodto include but not be
`
`limited to guidewires, balloon catheters, stents and stent catheters”). Patent
`
`Owner summarizes the method described in the ’413 patent and notes the
`
`use of the tapered innercatheter is optional. See PO Resp.3 (stating that
`
`“To|ptionally, a tapered inner catheter may be inserted with the coaxial guide
`
`catheter and advancedto the second vessel, and removed before an
`
`[interventional cardiology device] is inserted into the coaxial guide catheter”
`
`(citing Ex. 1001, 9:55—66).
`
`   ÿ
`
`
ÿ ÿ ÿ
`ÿ
` ÿÿÿÿÿ
` ÿ  ÿ!"
` # $ÿ %
` ÿ& %
ÿ
'(ÿ
`)#
'*
#+
`,ÿ-
`'.#+,+$/ÿ.
*#-
"0ÿ#"ÿ +ÿ1
ÿ2 .
'" ++.ÿ +ÿ# -,2.
ÿ12 ÿ + ÿ1
ÿ
`,#(#
.ÿ +ÿ$2#.
3#'
"ÿ1
`,,++ ÿ-
` %
'"ÿ"
"ÿ
` .ÿ"
ÿ-
` %
'"456ÿÿ
`
ÿ
`73
'ÿ"2((
`'#8
"ÿ %
ÿ(
%+.ÿ.
"-'#1
.ÿ# ÿ %
ÿ0ÿ9
`
ÿ
` .ÿ +
"ÿ %
ÿ
`2"
ÿ+:ÿ %
ÿ
`9
'
.ÿ#
'ÿ-
` %
'ÿ#"ÿ+9 #+
`,6ÿÿ;ÿ 7ÿ
"96ÿÿ!"
` # $ÿ %
` ÿ
`&<+=9 #+
`,,/ÿ
`ÿ
`9
'
.ÿ#
'ÿ-
` %
'ÿ(
`/ÿ1
ÿ# "
'
.ÿ3# %ÿ %
ÿ-+
`>#
`,ÿ$2#.
ÿ
`-
` %
'ÿ
` .ÿ
`.*
` -
.ÿ +ÿ %
ÿ"
-+ .ÿ*
""
,ÿ
` .ÿ'
(+*
.ÿ1
:+'
ÿ
` ÿ
`<#
'*
#+
`,ÿ-
`'.#+,+$/ÿ.
*#-
=ÿ#"ÿ# "
'
.ÿ# +ÿ %
ÿ-+
`>#
`,ÿ$2#.
ÿ-
` %
'4ÿ
`!-# # $ÿ?>6ÿÿ 56ÿ
`@ÿBCDCEÿFGÿHÿCIÿJKLMÿNCOCÿ
`
# #+
'ÿ-%
`,,
$
"ÿ-,
`#("ÿÿ ÿÿÿ
` .ÿPÿ+:ÿ %
ÿ0ÿ9
`
6ÿÿ
`
6ÿ6ÿÿQ,
`#(ÿÿ'
9'+.2-
.ÿ1
,+3ÿ#"ÿ %
ÿ+ ,/ÿ# .
9
.
ÿ-,
`#(ÿ+:ÿ
` %
ÿ0ÿ9
`
ÿ
` .ÿ#"ÿ#,,2" '
` #*
ÿ+:ÿ %
ÿ-,
`#(
.ÿ"21R
- ÿ(
`
'6ÿÿ
`6ÿÿSÿ(
%+.ÿ+:ÿ9'+*#.# $ÿ1
`-T29ÿ"299+' ÿ:+'ÿ
` ÿ#
'*
#+
`,ÿ
`-
`'.#+,+$/ÿ.
*#-
ÿ:+'ÿ2"
ÿ# ÿ %
ÿ-+'+
`'/ÿ*
`"-2,
` 2'
ÿ %
ÿ
`#
'*
#+
`,ÿ-
`'.#+,+$/ÿ.
*#-
ÿ1
# $ÿ
`.
`9
.ÿ +ÿ1
ÿ9
`""
.ÿ
` %'+2$%ÿ
`ÿ"
` .
`'.ÿ$2#.
ÿ-
` %
'ÿ %
ÿ"
` .
`'.ÿ$2#.
ÿ-
` %
'ÿ
`%
`*# $ÿ
`ÿ-+ # 2+2"ÿ,2(
ÿ
>
.# $ÿ:+'ÿ
`ÿ9'
.
:#
.ÿ,
$ %ÿ
`:'+(ÿ
`ÿ9'+>#(
`,ÿ
.ÿ
` ÿ
`ÿ%
(+"
` #-ÿ*
`,*
ÿ +ÿ
`ÿ.#"
`,ÿ
.ÿ
`.
`9
.ÿ
` +ÿ1
ÿ9,
`-
.ÿ# ÿ
`ÿ1'
` -%ÿ
`'
'/ÿ %
ÿ-+ # 2+2"ÿ,2(
ÿ+:ÿ %
ÿ$2#.
ÿ
`-
` %
'ÿ%
`*# $ÿ
`ÿ-#'-2,
`'ÿ-'+"""
- #+
`,ÿ#
'ÿ.#
`(
'ÿ"#8
.ÿ
`"2-%ÿ %
` ÿ#
'*
#+
`,ÿ-
`'.#+,+$/ÿ.
*#-
"ÿ
`'
ÿ# "
'
`1,
ÿ# +ÿ
`
` .ÿ %'+2$%ÿ %
ÿ,2(
ÿ %
ÿ(
%

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket